Acasti Pharma announced topline results from the phase 3 trial, TRILOGY 1, which was designed to determine the efficacy of CaPre compared to placebo in lowering fasting triglyceride (TG) levels in patients with severe hypertriglyceridemia. Despite positive results in...
Allena Pharmaceuticals announced positive topline results from URIROX-1, a Phase 3 pivotal trial evaluating reloxaliase in patients with enteric hyperoxaluria (EH). The primary endpoint was achieved, showing a statistically significant reduction in urinary oxalate in...
Clinuvel announced the U.S FDA has approved Scenesse (afamelanotide) to increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria (EPP). With this approval, Scenesse is the first...
Moderna Therapeutics announced the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for mRNA-3927, its investigational mRNA therapeutic for propionic acidemia (PA), a rare metabolic disease. With the...
High Point Clinical Trials Center LLC, the largest independent clinical research unit in North Carolina, announced its participation in the NASH PASS network. NASH PASS is organized and managed by metabolic disease specialist CRO ProSciento. Who is High Point Clinical...
High Point Clinical Trials Center, LLC (HPCTC), the largest independent clinical research site in North Carolina, reports it has partnered with ProSciento, a specialized CRO exclusively focused on metabolic diseases, to join as a NASH PASS site partner. ProSciento has...
